感染性休克血管活性药物选择策略  

Strategy for selection of vasoactive drugs in treatment of patients with septic shock

作　　者：胡才宝[1] 严静[1] 

机构地区：[1]浙江医院重症医学科,杭州310013

出　　处：《中国实用内科杂志》2015年第11期900-903,共4页Chinese Journal of Practical Internal Medicine

基　　金：卫生公益性行业科研专项经费项目(201202011);浙江省科技厅重症医学重点科技创新团队项目(2011R50018-02);浙江省中医药重点研究项目(2011ZZ001);浙江省医药卫生科技计划研究项目(2013KYB004)

摘　　要：在重症监护病房(ICU)中,管理严重感染和感染性休克患者是重症医生日常工作,因为感染性休克是ICU患者死亡的主要原因。应用血管活性药物是治疗感染性休克重要的循环支持手段。近年来,血管活性药物的应用和疗效在不断进行重新评价。2012年《严重感染和感染性休克国际治疗指南》以及2014年《中国严重脓毒症/脓毒性休克治疗指南》进一步就感染性休克患者血管活性药物的应用提出了推荐性的意见,值得临床医师重视。Management of patients with severe sepsis and septic shock is almost a daily exercise in most intensive care units, because septic shock may be the leading cause of death in ICUs. Unfortunately, despite all the efforts expended in this area, the mortality in these conditions has changed little over the years. Applications of vasoactive drugs are important means to support circulation in patients with septic shock. In recent years, their applications and and efficacies were being evaluated constantly. Applications of vasoactive drugs are also recommended by International Guidelines for Management of Severe Sepsis and Septic Shock（2012） and Chinese Guidelines for Management of Severe Sepsis and Septic Shock（2014）, which should be paid attention to by clinical doctors.

关 键 词：血管活性药物 感染性休克 血流动力学 多巴胺 去甲肾上腺素 

分 类 号：R631.4[医药卫生—外科学]